Intracellular delivery of biological effectors

Details Intracellular delivery of biological effectors Intracellular delivery of biological effectors

2006-04-25

2006-04-25

Ponnaluri, Padmashri (Department: 1639)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C514S002600, C530S300000, C530S326000, C530S327000, C530S810000, C435S069100, C435S320100

Reexamination Certificate

active

07033597

ABSTRACT:
The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.

REFERENCES:
patent: 2094658 (1993-04-01), None
patent: 2 767 323 (1999-02-01), None
patent: WO 94/23751 (1994-10-01), None
patent: WO 98/51325 (1998-11-01), None
patent: WO 98/51825 (1998-11-01), None
patent: WO 99/07414 (1999-02-01), None
patent: WO 00/12587 (2000-03-01), None
patent: WO 01/64738 (2001-09-01), None
patent: WO 02/31109 (2002-04-01), None
Anderson (1989).Clin. Immun. and Immunopathol. 53: S63-S71.
Ammendrup, et al. (2000).Diabetes 491468-1476.
Bleich, et al. (1999).J. Clin. Invest. 103(10): 1431-1436.
Bonner-Weir (1994)Recent Prog. Hormone Res. 49: 91-104.
Bonny, et al. (2001).Diabetes 50: 77-82.
Breeman, et al. (1999).Int. J. Cancer 81: 658-665.
Brugidou, et al. (1995).Biochem. Biophys. Res. Commun. 214(2): 685-693.
Burns, et al. (1998)J. Biol. Chem. 273(20): 12203-12209.
Chen, et al. (2000).Diabetes 49: 562-570.
Dupraz, et al. (1999).Gene Therapy 6: 1160-1169.
Efrat, et al. (1988).Proc. Natl. Acad. Sci. USA 85: 9037-9041.
Flodstrom, et al. (1999).Diabetes 48: 706-713.
Giannoukakis, et al. (1999).Diabetes 48: 1730-1736.
Gibbs (2000).Science 287: 1969-1973.
Gibbs and Oliff (1994).Cell 79: 193-198.
Hofland, et al. (1999).Proc. Assoc. Am. Physicians 111(1): 63-69.
Ivanenkov, et al. (1999).Biochem. Biophys. Acta 1448: 463-472.
Ivanenkov. et al. (1999).Biochem. Biophys. Acta 1448: 450-462.
Cabibbo, et al. (1995).Gene 167: 41-47.
Iwahashi, et al. (1996).Diabetologia 39: 530-536.
Iwahashi, et al. (1998).Cytokines, Cell Mol. Ther. 4: 45-51.
de Jong, et al. (1999).J. Nucl. Med. 40: 2081-2087.
Kato and Sugiyama (1997).Critical Rev Thera. Drug Carr. Systems 14(3): 287-331.
Kim, et al. (2000).Anticancer Res. 20: 439-444.
Larsen, et al. (1998).J. Biol. Chem. 273(24) 15294-15300.
Lin, et al. (1995).J. Biol. Chem. 270(24) 14255-14258.
Lund, et al. (1990).J. Biol. Chem. 265(25): 15713-15723.
Mahato, et al. (1997).Critical Rev. Thera Drug Carr Systems 14(2): 133-172.
Mahato, et al. (1997).J. Drug Targeting 4(6): 337-357.
Mandrup-Poulsen (1996).Diabetologia 39 1005-1029.
Mandrup-Poulsen (1998).BMJ 316: 1221-1225.
Mukherjee, et al. (1997).Physiol. Rev. 77(3): 759-803.
Negri, et al. (2000).Genomics 64: 324-330.
Nerup, et al. (1988).Diabetes Care 11(supp. 1): 16-23.
Oehlke, et al. (1998).Biochem. Biophys. Acta 1414: 127-139.
Offord, et al. (1997).Meth. Enzymol. 287348-369.
Pasqualini and Ruoslahti (1996).Mol. Psychiatry 1: 423.
Peralta, et al. (1990).Endocrinol. 127(2): 595-603.
Rabinovitch, et al. (1999).Diabetes 481223-1229.
Renschler, et al (1994).Proc. Natl. Acad. Sci USA 91: 3623-3627.
Roitt (1991).Essential Immunology.Chapter 4: 65-83.
Rose and Vizzavona (1999)J. Am. Chem Soc. 121: 7034-7038.
Rouquet, et al. (1996).Curr. Biol. 6(9): 1192-1195.
Scharfmann and Czernichow (1996).Diabetes and Metabolism 22: 223-228.
Schwarze, et al. (1999).Science 285: 1569-1572.
Scott and Smith (1990).Science 249: 386-390.
Sjoholm (1998).Cell Death Diff. 5: 461-468.
Smith and Jarrett (1988).Laboratory Invest. 58(6): 613-629.
Smith and Scott (1993).Meth. Enzymol. 217: 228-257.
Stephens, et al. (1997).J. Autoimmunity 10: 293-298.
Stephens, et al. (1999).Endocrinol. 140(7): 3219-3227.
Suzuki, et al. (2002).J. Biol Chem. 277(4): 2437-2443.
Terskikh, et al. (1997).Proc. Natl. Acad. Sci. USA 94: 1663-1668.
Thorens (1992).Proc. Natl. Acad. Sci. USA 89: 8641-8645.
Torgerson, et al. (1998).J. Immunology 161: 6084-6092.
Ulbrich, et al. (2000).J. Controlled Rel. 64: 63-79.
Usami, et al. (1998).Biochem Pharmacol 55: 185-191.
Wang, et al. (1999).Endocrinol. 140(3): 1200-1204.
Welsh, et al. (1999).Mol. Med. 5: 169-180.
Widmann, et al. (1995).Biochem J. 315: 203-214.
Yamada, et al (1999).Diabetes 48: 478-483.
Yoon, et al. (1999).Science 284: 1183-1187.
York, et al. (1999).J. Biol Chem. 274(2): 1164-1171.
Zacher, et al. (1980).Gene 9: 127-140.
Zeng, et al. (1996).J. Peptide Sci. 2: 66-72.
Zwick, et al. (1998).Curr. Opin. Biotech. 9: 427-436.
Pasquallini and Ruoslahti (1996).Nature 380364-366.
Sela and Zisman (1997).FASEB J. 11: 449-456.
Volz, et al. (1995).FEBS Letters 373: 23-29.
Yamato, et al. (1997).Horm. Metab. Res. 29: 56-59.
Bonny, et al. (2000).J. Biol. Chem. 275(22): 16466-16472.
Hoorens, et al. (1996).J. Clin. Invest. 98(7): 1568-1574.
Bonny, et al. (1998).J. Biol. Chem. 273(4): 1843-1846.
Sela and Zisman (1997).FASEB J. 11: 449-456.
Gotoh, et al. (1987).Transplantation 43(5): 725-730.
Carithers and Lerner (1996).Chem. Biol. 3: 537-542.
Damke (1996).FEBS Letters 389: 48-51.
Hawiger (1999).Current Opinion Chem. Biol. 3: 89-94.
Avrameas, et al. (1998).Proc. Natl. Acad. Sci. USA 95: 5601-5606.
Rothbard, et al. (2000).Nature Med. 6(11): 1253-1257.
International Search Report for PCT/ IB01/ 02423. Mailed on Jul. 2, 2002.
International Search Report for PCT/IB03/03097, mailed Sep. 30, 2004.

Affiliated with

Also associated with

Rating

Intracellular delivery of biological effectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intracellular delivery of biological effectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intracellular delivery of biological effectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3611199